Document:

EX-4.6

 Exhibit 4.6 

DESCRIPTION OF THE REGISTRANT’S SECURITIES 

REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 

The following summary describes all material provisions of the common stock, par value $0.0001 per share, of Foghorn Therapeutics Inc. The description of our
common stock is qualified by reference to our certificate of incorporation, bylaws, and investor rights agreement, which are included as exhibits to the Annual Report on Form 10-K of which this Exhibit 4.6 is
a part. The summary below is also qualified by provisions of applicable law. 
 General 

Our authorized capital stock consists of 175,000,000 shares of common stock, par value $0.0001 per share, and 25,000,000 shares of preferred stock, par value
$0.0001 per share. Our common stock is registered under Section 12 of the Securities Exchange Act of 1934, as amended, and is listed on The Nasdaq Global Market under the symbol “FHTX.”  

Common Stock 
 Holders of our common stock are entitled to
one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled
to vote on the election. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate
and issue in the future. 
 In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately our net
assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or
conversion rights. Our outstanding shares of common stock are validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders
of shares of any series of preferred stock that we may designate and issue in the future. 
 Preferred Stock 

Under the terms of our amended and restated certificate of incorporation, our board of directors is authorized to direct us to issue shares of preferred stock
in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and
liquidation preferences, of each series of preferred stock. 
 The purpose of authorizing our board of directors to issue preferred stock and determine its
rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate
purposes, could have the effect of making it more difficult for a third-party to acquire, or could discourage a third-party from seeking to acquire, a majority of our outstanding voting stock. 

Anti-Takeover Effects of our Certificate of Incorporation and our By-Laws 

Our certificate of incorporation and by-laws contains certain provisions that are intended to enhance the
likelihood of continuity and stability in the composition of our board of directors but which may have the effect of delaying, deferring or preventing a future takeover or change in control of us unless such takeover or change in control is approved
by our board of directors. 
 These provisions include: 

Classified board. Our certificate of incorporation provides that our board of directors will be divided into three classes of directors, with the
classes as nearly equal in number as possible. As a result, approximately one-third of our board of directors are elected each year. The classification of directors has the effect of making it more
difficult for stockholders to change the composition of our board. Our certificate of incorporation also provides that, subject to any rights of holders of preferred stock to elect additional directors under specified circumstances, the number of
directors will be fixed exclusively pursuant to a resolution adopted by our board of directors. 

 Action by written consent; special meetings of stockholders. Our certificate of incorporation
provides that stockholder action can be taken only at an annual or special meeting of stockholders and cannot be taken by written consent in lieu of a meeting. Our certificate of incorporation and
the by-laws also provides that, except as otherwise required by law, special meetings of the stockholders can only be called pursuant to a resolution adopted by a majority of our board of directors.
Except as described above, stockholders are not permitted to call a special meeting or to require our board of directors to call a special meeting. 

Removal of directors. Our certificate of incorporation provides that our directors may be removed only for cause by the affirmative vote of at
least 75% of the voting power of our outstanding shares of capital stock, voting together as a single class. This requirement of a supermajority vote to remove directors could enable a minority of our stockholders to prevent a change in the
composition of our board. 
 Advance notice procedures. Our by-laws establish an advance
notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to the board of directors. Stockholders at an annual meeting are only able to consider
proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to
vote at the meeting and who has given our Secretary timely written notice, in proper form, of the stockholder’s intention to bring that business before the meeting. Although the by-laws do not give our
board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting, the by-laws may have
the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or
otherwise attempting to obtain control of us. 
 Supermajority approval requirements. The DGCL generally provides that the affirmative vote of a
majority of the shares entitled to vote on any matter is required to amend a corporation’s certificate of incorporation or by-laws, unless either a corporation’s certificate of incorporation or by-laws requires a greater percentage. Our certificate of incorporation and by-laws provide that the affirmative vote of holders of at least 75% of the total
votes eligible to be cast in the election of directors is required to amend, alter, change or repeal specified provisions. This requirement of a supermajority vote to approve amendments to our certificate of incorporation and by-laws could enable a minority of our stockholders to exercise veto power over any such amendments. 
 Authorized but
unissued shares. Our authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval. These additional shares may be utilized for a variety of corporate purposes, including
future public offerings to raise additional capital, corporate acquisitions and employee benefit plans. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt to
obtain control of a majority of our common stock by means of a proxy contest, tender offer, merger or otherwise. 
 Exclusive forum. Our
certificate of incorporation requires, to the fullest extent permitted by law, that derivative actions brought in the name of the Company, actions against directors, officers and employees for breach of a fiduciary duty and other similar actions may
be brought only in specified courts in the State of Delaware. Although we believe this provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, the provision may have
the effect of discouraging lawsuits against our directors and officers. See “Risk Factors—Our amended and restated certificate of incorporation designates the state or federal courts within the State of Delaware as the exclusive forum for
certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.” 

Section 203 of the DGCL 
 We are subject to
the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a publicly-held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a three-year period
following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. A “business combination” includes, among other things, a merger, asset or stock sale or other
transaction resulting in a financial benefit to the interested stockholder. An “interested stockholder” is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested
stockholder status, 15% or more of the corporation’s voting stock. 

  
 -2- 

 Under Section 203, a business combination between a corporation and an interested stockholder is
prohibited unless it satisfies one of the following conditions: before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested
stockholder; upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction
commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or at or after the time the stockholder became interested, the
business combination was approved by our board of directors of the corporation and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the
outstanding voting stock which is not owned by the interested stockholder. 
 A Delaware corporation may “opt out” of these provisions with an
express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or by-laws resulting from a stockholders’ amendment approved by at least a
majority of the outstanding voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented. 

Transfer Agent and Registrar 
 The transfer agent and
registrar for our common stock is Computershare Trust Company, N.A. 

  
 -3-EX-10.18

 Exhibit 10.18 

 

			
	

	  	Execution Version

 October 29, 2020 
 Cigall
Kadoch, Ph.D. 
 By Email Delivery 
 Dear Dr. Kadoch: 

Reference is made to that certain letter agreement dated October 1, 2015, by and between you and Foghorn Therapeutics Inc. (the
“Company”), as amended by that certain fee increase letter dated January 22, 2019 (such agreement, as so amended, the “Consulting Agreement”). The purpose of this letter (this “Amendment”) is
to amend certain terms of the Consulting Agreement, as described below. 
 A.    Term of Consulting Agreement 

Section 6(a) of the Consulting Agreement is hereby amended and replaced in its entirety as follows: 

The “Term” shall commence on the Effective Date and shall continue until January 1, 2022, unless
earlier terminated in accordance with this Section 6. Notwithstanding the foregoing, from and after January 1, 2022, the Term shall be extended automatically for each successive one- (1) year
period unless the Company provides you written notice no later than the immediately preceding December 1 of its intention not to renew the Term. 

B.    Compensation 
 Section 8(b)
of the Consulting Agreement is hereby amended and replaced in its entirety as follows: 
 Effective as of October 1,
2020, and continuing until the expiration or termination of this Agreement, the Company will pay you consulting fees, payable monthly in arrears, in a monthly amount as set forth below. 

 

					
	 Month
	  	Monthly
Consulting Fee	 
	 October 2020
	  	$	18,750	 
	 November 2020
	  	$	16,000	 
	 December 2020
	  	$	16,000	 
	 January 2021
	  	$	14,000	 
	 February 2021
	  	$	14,000	 
	 March 2021
	  	$	12,000	 
	 April 2021
	  	$	12,000	 
	 May 2021 and thereafter
	  	$	9,580	 

 C.    Confidentiality 

Section 3(c) of the Consulting Agreement is hereby amended to include the following at the end of the Section: 

Further, (i) nothing contained in this Agreement limits, restricts or in any other way affects your communicating with
any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to such governmental agency or entity; and (ii) you will not be held criminally or civilly
liable under any federal or state trade secret law for disclosing a trade secret (A) in confidence to a federal, state or local government official, directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating
a suspected violation of law, or (B) in a complaint or other document filed under seal in a lawsuit or other proceeding, provided, however, that notwithstanding this immunity from liability, you may be held liable if you
unlawfully access trade secrets by unauthorized means. 
 D.    Limits on Competition 

Section 5(a)(i) is hereby deleted from the Consulting Agreement (with the defined term “Restricted Territory” surviving). 

In order to protect the Company’s legitimate business interests, you agree, as a condition of the extension of the Term as provided herein and in
exchange for the compensation and benefits provided hereunder, to which you are not otherwise entitled, to enter into the Non-Competition, Non-Solicitation,
Confidentiality and Assignment of Inventions Agreement (the “Confidentiality Agreement”) attached as Exhibit A hereto. You must sign and return the Confidentiality Agreement in connection with the execution
of this Amendment. 
 You acknowledge and agree that references to employment or termination of employment included in the Confidentiality Agreement will be
deemed to refer, respectively, to your services to the Company, under the Consulting Agreement or otherwise, or the termination thereof. 
 Notwithstanding
anything to the contrary in the Confidentiality Agreement, the restrictions set forth in Sections 8 (Non-Competition) and 9 (Non-Solicitation) of the
Confidentiality Agreement will not apply to activities conducted on behalf of DFCI (as defined in the Consulting Agreement) or any other academic, hospital, governmental or
not-for-profit institution or entity that employs you or for which you consult or otherwise provide services, now or in the future, including the Broad Institute,
Harvard University, Stanford University and the Howard Hughes 

  
 -2- 

 
Medical Institute (collectively, “Institutions”), or to any seminars, talks or other educational activities you may undertake in your capacity as an employee or consultant of an
Institution, provided that you comply with the other terms of the Consulting Agreement and the Confidentiality Agreement. 

E.    Miscellaneous 
 Except as
expressly amended by this Amendment, the Consulting Agreement will remain in full force and effect in accordance with its terms. This Amendment will be governed by and construed and enforced in accordance with the laws of the Commonwealth of
Massachusetts, without giving effect to the conflict of law principles of any jurisdiction. This Amendment may be executed in one or more counterparts (and may be delivered by email or other electronic means), each of which will be deemed an
original but all of which together will constitute one and the same instrument. 
 [Remainder of Page Intentionally Left Blank] 

  
 -3- 

 Please sign below to acknowledge your acceptance of the terms of this letter. Keep one copy for your files
and return one executed copy to the Company. 
  

			
	 Very truly yours,
  

FOGHORN THERAPEUTICS INC.

		
	By:	 	/s/ Adrian Gottschalk
	Name:	 	Adrian Gottschalk
	Title:	 	President and CEO

  

	
	Accepted and agreed:
	
	/s/ Cigall Kadoch
	Cigall Kadoch

 [Signature Page to Letter Agreement] 

 Exhibit A 

NON-COMPETITION, NON-SOLICITATION, CONFIDENTIALITY 

AND ASSIGNMENT OF INVENTIONS AGREEMENT 

(attached)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]